V8 Peptides — Engineered Performance
Research Library
Hexarelin Dose Reporting in Published Animal Studies
HexarelinPreclinical

Hexarelin Dose Reporting in Published Animal Studies

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

Published hexarelin studies do not share one standard protocol. Rodent and dog papers report quantities per kilogram of body mass (from 10 to 500 µg/kg per day), delivered subcutaneously, intravenously, intraperitoneally, orally by gavage or by osmotic pump for anything from a single exposure to 16 weeks, while cell and isolated-heart work uses nanomolar to low-micromolar concentrations. Two things recur: the growth hormone response to repeated exposure fades (desensitization), and circulating IGF-1 was usually unchanged. For the bench, the only arithmetic needed is concentration = mass ÷ volume; the 5 mg research vial gives 2.5 mg/mL in 2 mL of diluent. For laboratory research use only; not for human consumption.

A search for hexarelin "protocols" mostly turns up lists of numbers with no source. This article does the opposite: it reads what the primary papers actually reported, tabulates the study parameters as published, and then shows the unit arithmetic that connects a lyophilized research vial to those reported conditions. Nothing here is guidance for people or a recommendation of any quantity; every figure describes what a specific animal or cell experiment used. Hexarelin from the product page is a research material, and the background on the compound itself is in the hexarelin research overview.

Why published hexarelin parameters are hard to compare

Hexarelin is a synthetic hexapeptide agonist of the ghrelin receptor GHS-R1a, and it also binds the scavenger receptor CD36 in heart tissue (Bodart and colleagues, 2002). That dual pharmacology is one reason the literature is spread across endocrinology, cardiology and metabolism, and each field built its own protocol conventions. A pituitary physiologist measures a hormone pulse minutes after a single intravenous bolus. A cardiac group ligates a coronary artery and follows echocardiography for two weeks. A cell biologist exposes cultured cells to a defined molar concentration for hours.

Those designs are not interchangeable. A figure quoted in micrograms per kilogram describes an animal of a particular species, age and body mass; a figure in nanomolar describes a medium. Handling them as one scale is the most common error in secondary summaries. The sections below keep the three groups separate.

Reported parameters in rodent and dog studies

The table lists parameters exactly as stated in the abstracts of the cited papers. It is a map of the literature, not a menu. Where an abstract did not state a quantity, the cell says so rather than guessing.

StudyModelReported quantity and routeDurationMain reported outcome
Cattaneo and colleagues, 1997Aged rats80 µg/kg, subcutaneous30 and 60 daysGH-releasing effect maintained; circulating IGF-1 not altered
Conley and colleagues, 1998Adult male rats25 µg/kg intravenous boluses at 2 h intervals; separate continuous infusions at 100 µg/h3 boluses; infusions of 6, 30 or 174 hSecond bolus gave a smaller GH response; infusion raised GH briefly, then it returned to basal
Rigamonti and colleagues, 1999Young beagle dogs250 µg/kg subcutaneous, twice daily6 weeksGH peak response rose to week 3, then fell below baseline by week 6
Cella and colleagues, 1996Aged beagle dogs500 µg/kg per day, subcutaneous16 weeks in three on-periodsGH response rose then fell in each period; IGF-I unchanged
Locatelli and colleagues, 1999Hypophysectomized rats80 µg/kg, subcutaneous7 daysProtection of isolated hearts from ischemia-reperfusion damage, reported as GH-independent
Tivesten and colleagues, 2000Rats after coronary ligation10 or 100 µg/kg per day, subcutaneous, twice daily2 weeksHigher dose raised stroke volume and cardiac output on echocardiography
Huang and colleagues, 2017Rats after ischemia-reperfusion100 µg/kg per day, subcutaneous, twice daily7 daysImproved systolic function; IL-1 pathway changes
Zhang and colleagues, 2018Streptozotocin-diabetic rats100 µg/kg, daily2 weeksPulsatile GH normalized; IGF-1 not recovered
Mosa and colleagues, 2017MKR insulin-resistant mice200 µg/kg, intraperitoneal, twice daily12 daysImproved glucose handling and lipid readouts
Huang and colleagues, 2021MC4RKO obese mice10.56 µg per day by osmotic pump3–4 weeksPulsatile GH raised; IGF-1 unchanged
Mao and colleagues, 2014Mice after myocardial infarctionSingle oral gavage; quantity not stated in the abstractOne exposureHigher ejection fraction at the chronic stage

Three patterns stand out. First, route varies as widely as quantity: oral gavage, osmotic pump and intraperitoneal delivery all appear, so a number from one route says little about another. Second, the longest studies were designed around the pituitary axis and the shortest around the heart. Third, the endocrine papers are the ones that tested repeat exposure systematically, and they agree that the response changes with time.

Cell and isolated-organ concentrations

In vitro work states concentration, not mass per body weight, and the numbers are small. Isolated mouse hearts were perfused with 1 nM hexarelin in a Langendorff preparation (Ma and colleagues, 2012). Cultured pancreatic beta-cell lines were exposed to 1.0 µM hexarelin in a streptozotocin-damage model (Zhao and colleagues, 2016). The gap between 1 nM and 1 µM is a thousand-fold, which shows how much the reported working range depends on the endpoint, the cell type and the exposure time.

PreparationReported concentrationReadout
Isolated mouse heart (Langendorff)1 nM, in perfusate before or after ischemiaCell shortening, intracellular calcium transients, phospholamban phosphorylation
MIN6 mouse beta-cell line1.0 µM, with streptozotocin challengeMitochondrial membrane signal, superoxide, caspase and Bax/Bcl-2 markers
Rat cardiac membranesRadiolabeled hexarelin derivative as binding probeIdentification of CD36 as an 84 kDa binding protein

For a lab, the practical consequence is that a stock concentration should be chosen from the dilution needed for the lowest working point, not from the vial size. A single concentrated stock can serve a nanomolar-to-micromolar series if the dilution scheme is planned in advance.

Desensitization: the pattern most papers share

The endocrine studies converge on one result. Repeated or continuous exposure changes the GH response. In rats, a second intravenous bolus two hours after the first produced a significantly smaller GH peak, and continuous infusion produced a brief rise that returned to basal levels (Conley and colleagues, 1998). In young dogs the response to a challenge rose to a maximum at week 3 and then fell below baseline at week 6 (Rigamonti and colleagues, 1999). In aged dogs the same rise-then-fall pattern repeated in each on-period and reset after a wash-out interval (Cella and colleagues, 1996). A commentary on the question is titled, simply, whether desensitization to hexarelin occurs (Rahim and colleagues, 1998).

Not every model shows loss of responsiveness: aged rats exposed for 30 and 60 days retained the GH-releasing effect (Cattaneo and colleagues, 1997). The discrepancy illustrates why species, age and schedule must be stated with any quantity. A protocol is a combination of all of them, and published results belong to the combination, not to the number.

Stock-solution arithmetic, formulas only

The V8 hexarelin vial holds 5 mg of lyophilized peptide, and the product page gives its molecular formula as C47H58N12O6, which corresponds to roughly 887 g/mol. Three formulas cover almost every calculation:

  • Concentration (mg/mL) = vial mass (mg) ÷ diluent volume (mL).
  • Molarity (mol/L) = concentration (g/L) ÷ 887. A 1 mg/mL solution is therefore about 1.13 mM.
  • Dilution: C1V1 = C2V2, where 1 is the stock and 2 is the working solution.
Diluent added to 5 mg vialConcentration (mg/mL)Concentration (µg/mL)Approximate molarity
1 mL55,0005.6 mM
2 mL2.52,5002.8 mM
2.5 mL22,0002.3 mM
5 mL11,0001.1 mM

The product page's own example matches the second row: 2 mL of diluent gives 2.5 mg/mL, so a 40 µL aliquot contains 100 µg. To reach a 1 µM working solution in an in vitro series from the 2.8 mM stock, the dilution factor is 2.8 mM ÷ 1 µM, about 2,800-fold, which is best done in two steps instead of one to keep pipetting error low. For any other combination, the reconstitution calculator performs the same arithmetic, and the principles are explained in peptide reconstitution volume calculations and the reconstitution calculator guide.

Reading an animal-study quantity correctly

When a paper reports micrograms per kilogram, the amount per animal is the reported quantity multiplied by that animal's body mass in kilograms; the volume is the amount divided by the stock concentration in micrograms per microliter. The arithmetic is trivial, but three details are not. Is the quantity per administration or per day? The Tivesten and Huang cardiac papers describe the daily total given twice daily. Is it free peptide or a salt? Vial mass includes counter-ions and water, so net peptide content is lower than the label figure, as explained in understanding HPLC purity. Is the vehicle stated? Saline, buffered solution and water are not equivalent for a lyophilized material.

Handling and quality points that affect reproducibility

A reproduced experiment is only as consistent as its starting material. Hexarelin has two tryptophan residues, and peptides with aromatic side chains are prone to light-driven and oxidative change during forced degradation (Hawe and colleagues, 2012). Peptide loss to plastic and glass also lowers the delivered concentration of dilute solutions (Goebel-Stengel and colleagues, 2011). Practical consequences: keep the vial boxed, use low-binding tubes, make dilute working solutions on the day, and record lot number, diluent and date for every stock. Storage on the product page is refrigerate at 2–8 °C, −20 °C for long-term, away from heat, moisture and light; see storing research peptides for tiering and how to reconstitute a lyophilized peptide for the mechanics.

What the literature does not provide

No paper cited here defines a standard hexarelin protocol, and none should be read as one. The quantities above were chosen by individual investigators for specific hypotheses in specific animals, and several are explicitly from disease models such as coronary ligation, streptozotocin diabetes or genetic obesity. Abstracts do not report every parameter, so a faithful replication needs the full methods section. Nothing in these studies supports conclusions about people, and this article makes none.

Related reading

Frequently asked questions

Is there a standard hexarelin protocol for research?

No. Published studies use very different quantities, routes and durations depending on species and endpoint, and none defines a standard. Each paper's methods section is the only reliable source for that study's conditions.

What units do published hexarelin animal studies use?

Most report micrograms per kilogram of body mass, per administration or per day, while osmotic-pump studies report micrograms per day and cell studies report molar concentrations such as 1 nM or 1 µM.

How do I calculate hexarelin concentration from a 5 mg vial?

Divide the vial mass by the diluent volume. Two milliliters gives 2.5 mg/mL, one milliliter gives 5 mg/mL. Molarity follows by dividing the concentration in g/L by about 887.

Why does the growth hormone response change with repeated hexarelin exposure in animals?

Several rat and dog studies report desensitization: a smaller response to a second bolus, a brief rise during continuous infusion, or a rise and then fall over weeks. One aged-rat study found the response maintained over 30 and 60 days.

Does hexarelin change IGF-1 in animal studies?

In the aged-rat, aged-dog, diabetic-rat and obese-mouse papers cited here, circulating IGF-1 was reported as unchanged or not recovered, even when GH secretion increased.

What concentrations are used in cell studies with hexarelin?

Reported working concentrations include 1 nM in perfused mouse hearts and 1.0 µM in a beta-cell line, a thousand-fold range that reflects different endpoints and exposure times.

How should hexarelin stock be stored?

The product page states 2–8 °C, or −20 °C for long-term storage, protected from heat, moisture and light. Dilute working solutions are best prepared on the day of use.

Does this article give a quantity for people?

No. It reports what published animal and cell studies used and supplies formula-only laboratory arithmetic. Hexarelin is sold for laboratory research use only.

Related reading: Hexarelin Half-Life and Stability: What Is Published, Hexarelin Reconstitution Calculator: Math and Planning, Hexarelin Preclinical Studies: A Review by Model.

References

  1. Cattaneo L, Luoni M, Settembrini B, Müller EE, Cocchi D. Effect of long-term administration of Hexarelin on the somatotrophic axis in aged rats. Pharmacol Res. 1997;36(1):49-54. doi:10.1006/phrs.1997.0203
  2. Conley LK, Gaillard RC, Giustina A, Brogan RS, Wehrenberg WB. Effects of repeated doses and continuous infusions of the growth hormone-releasing peptide hexarelin in conscious male rats. J Endocrinol. 1998;158(3):367-75. doi:10.1677/joe.0.1580367
  3. Rigamonti AE, Cella SG, Marazzi N, Müller EE. Six-week treatment with hexarelin in young dogs: evaluation of the GH responsiveness to acute hexarelin or GHRH administration, and of the orexigenic effect of hexarelin. Eur J Endocrinol. 1999;141(3):313-20. doi:10.1530/eje.0.1410313
  4. Cella SG, Cerri CG, Daniel S, Sibilia V, Rigamonti A, Cattaneo L, et al.. Sixteen weeks of hexarelin therapy in aged dogs: effects on the somatotropic axis, muscle morphology, and bone metabolism. J Gerontol A Biol Sci Med Sci. 1996;51(6):B439-47. doi:10.1093/gerona/51a.6.b439
  5. Locatelli V, Rossoni G, Schweiger F, Torsello A, De Gennaro Colonna V, Bernareggi M, et al.. Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology. 1999;140(9):4024-31. doi:10.1210/endo.140.9.6948
  6. Tivesten A, Bollano E, Caidahl K, Kujacic V, Sun XY, Hedner T, et al.. The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction. Endocrinology. 2000;141(1):60-6. doi:10.1210/endo.141.1.7249
  7. Huang J, Li Y, Zhang J, Liu Y, Lu Q. The Growth Hormone Secretagogue Hexarelin Protects Rat Cardiomyocytes From in vivo Ischemia/Reperfusion Injury Through Interleukin-1 Signaling Pathway. Int Heart J. 2017;58(2):257-263. doi:10.1536/ihj.16-241
  8. Zhang X, Yang JK, Chen C. Enhanced Pulsatile Growth Hormone Secretion and Altered Metabolic Hormones by in Vivo Hexarelin Treatment in Streptozotocin-Induced Diabetic Rats. Int J Mol Sci. 2018;19(10):. doi:10.3390/ijms19103067
  9. Mosa R, Huang L, Wu Y, Fung C, Mallawakankanamalage O, LeRoith D, et al.. Hexarelin, a Growth Hormone Secretagogue, Improves Lipid Metabolic Aberrations in Nonobese Insulin-Resistant Male MKR Mice. Endocrinology. 2017;158(10):3174-3187. doi:10.1210/en.2017-00168
  10. Huang Z, Lu X, Huang L, Zhang C, Veldhuis JD, Cowley MA, et al.. Stimulation of endogenous pulsatile growth hormone secretion by activation of growth hormone secretagogue receptor reduces the fat accumulation and improves the insulin sensitivity in obese mice. FASEB J. 2021;35(1):e21269. doi:10.1096/fj.202001924RR
  11. Mao Y, Tokudome T, Kishimoto I, Otani K, Miyazato M, Kangawa K. One dose of oral hexarelin protects chronic cardiac function after myocardial infarction. Peptides. 2014;56:156-62. doi:10.1016/j.peptides.2014.04.004
  12. Ma Y, Zhang L, Edwards JN, Launikonis BS, Chen C. Growth hormone secretagogues protect mouse cardiomyocytes from in vitro ischemia/reperfusion injury through regulation of intracellular calcium. PLoS One. 2012;7(4):e35265. doi:10.1371/journal.pone.0035265
  13. Zhao Y, Zhang X, Chen J, Lin C, Shao R, Yan C, et al.. Hexarelin Protects Rodent Pancreatic Β-Cells Function from Cytotoxic Effects of Streptozotocin Involving Mitochondrial Signalling Pathways In Vivo and In Vitro. PLoS One. 2016;11(2):e0149730. doi:10.1371/journal.pone.0149730
  14. Bodart V, Febbraio M, Demers A, McNicoll N, Pohankova P, Perreault A, et al.. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res. 2002;90(8):844-9. doi:10.1161/01.res.0000016164.02525.b4
  15. Rahim A, Shalet SM. Does desensitization to hexarelin occur? Growth Horm IGF Res. 1998;8(Suppl B):141-143. doi:10.1016/S1096-6374(98)80039-7
  16. Hawe A, Wiggenhorn M, van de Weert M, Garbe JHO, Mahler HC, Jiskoot W. Forced degradation of therapeutic proteins. J Pharm Sci. 2012;101(3):895-913. doi:10.1002/jps.22812
  17. Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.